AbbVie: Game Changer

Summary:

  • AbbVie Inc. is showing signs of growth beyond the loss of exclusivity for Humira, with strong 2024 guidance.
  • Sales of Skyrizi and Rinvoq are replacing lost Humira sales, with projected sales more than doubling through 2027.
  • AbbVie’s acquisitions of ImmunoGen and Cerevel Therapeutics are expected to further boost sales, though add $18.7 billion to debt.
  • The stock is relatively cheap, trading at 14x ’25 EPS targets.

Abbvie Ahead Of Earnings Figures

Bloomberg/Bloomberg via Getty Images

Even before a couple of major acquisitions close and impact results, AbbVie Inc. (NYSE:ABBV) is showing solid signs of growing beyond the Humira loss of exclusivity. The stock has already soared to yearly highs


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


If you’d like to learn more about how to best position yourself in under valued stocks mispriced by the market to start 2024, consider joining Out Fox The Street

The service offers a model portfolio, daily updates, trade alerts and real-time chat. Sign up now for a risk-free 2-week trial to started finding the best stocks with potential to double and triple in the next few years. 

Leave a Reply

Your email address will not be published. Required fields are marked *